267 related articles for article (PubMed ID: 33720068)
1. Emerging systemic antitarget treatment for differentiated thyroid carcinoma.
Basté N; Mora M; Grau JJ
Curr Opin Oncol; 2021 May; 33(3):184-195. PubMed ID: 33720068
[TBL] [Abstract][Full Text] [Related]
2. An update on clinical trials of targeted therapies in thyroid cancer.
Haraldsdottir S; Shah MH
Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
5. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
[TBL] [Abstract][Full Text] [Related]
6. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
San Román Gil M; Pozas J; Molina-Cerrillo J; Gómez J; Pian H; Pozas M; Carrato A; Grande E; Alonso-Gordoa T
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668761
[TBL] [Abstract][Full Text] [Related]
7. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Cabanillas ME; Ryder M; Jimenez C
Endocr Rev; 2019 Dec; 40(6):1573-1604. PubMed ID: 31322645
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].
Malouf G; Baudin E; Soria JC; Schlumberger M
Bull Cancer; 2009 Jan; 96(1):95-101. PubMed ID: 19211364
[TBL] [Abstract][Full Text] [Related]
10. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
Bulotta S; Celano M; Costante G; Russo D
Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
[TBL] [Abstract][Full Text] [Related]
13. Target therapies for radioiodine refractory advanced thyroid tumors.
Schlumberger M
J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
[TBL] [Abstract][Full Text] [Related]
14. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
Hamidi S; Hofmann MC; Iyer PC; Cabanillas ME; Hu MI; Busaidy NL; Dadu R
Front Endocrinol (Lausanne); 2023; 14():1176731. PubMed ID: 37435488
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid cancer: a promising model for targeted therapy.
Torino F; Paragliola RM; Barnabei A; Corsello SM
Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
17. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
18. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
20. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
